Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354484 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
NCT00354484 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 291 participants.
The verdict
NCT00354484, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIT45 compared to the current standard of care in postpartum patients.
Interventions
- DRUG Ferric Carboxymaltose (FCM)
- DRUG Ferrous Sulfate tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00354484
The ClinicalTrials.gov registry entry for NCT00354484 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric Carboxymaltose (FCM) is the first listed.
NCT00354484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00354484 about?
NCT00354484 is a clinical study titled "Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients". The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIT45 compared to the current standard of care in postpartum patients.
What is the current status of trial NCT00354484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2006-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00354484?
The interventions under investigation include: Ferric Carboxymaltose (FCM) (DRUG), Ferrous Sulfate tablets (DRUG).
Who is sponsoring clinical trial NCT00354484?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.